Transplant drug 2-year study outcomes show superior kidney function
Sunday, May 2, 2010 - 19:51
in Health & Medicine
SAN DIEGO -- Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.